Anti-PD-1 Therapy for Melanoma Associated With Chronic Immune-Related Adverse Events
Drug Topics
SEPTEMBER 5, 2023
The majority of persistent irAEs were hypothyroid, adrenal insufficiency, arthritis, dermatitis or pruritis, and hypophysitis.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Drug Topics
SEPTEMBER 5, 2023
The majority of persistent irAEs were hypothyroid, adrenal insufficiency, arthritis, dermatitis or pruritis, and hypophysitis.
European Pharmaceutical Review
OCTOBER 20, 2022
Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?mediated What are Tregs and how are they applicable to immune-mediated disease?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 7, 2020
A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. For our vaccine, we use two different adenovirus vectors in a bid to avoid the immune system becoming immune to the vector.”.
Pharmacy Times
SEPTEMBER 14, 2023
Compared with COVID-19 vaccination alone, recent study findings show health care workers who received both a COVID-19 booster and influenza vaccinations did not have lower immune response or more frequent adverse events.
Drug Store News
JANUARY 10, 2023
Events will be held at Walmart pharmacies nationwide on Saturday, Jan.
Pharmacy Times
APRIL 30, 2024
According to the speaker, the complexity of immune-related adverse events resulting from immune checkpoint inhibitors requires a lot of collaborative discussion between patients and providers.
Pharmacy Times
OCTOBER 3, 2024
By utilizing a lower dose, patients can avoid potential adverse events and high financial burden.
pharmaphorum
NOVEMBER 1, 2024
The 8th Antigen-Specific Immune Tolerance Drug Development Summit is an event organised by Hanson Wade. Discover the latest developments and networking opportunities at this leading industry conference.
pharmaphorum
DECEMBER 4, 2020
The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. The post 4th Antigen Specific Immune Tolerance Summit appeared first on.
STAT
OCTOBER 14, 2024
Jasper Therapeutics, a biotech looking to make stem cell transplants less taxing and to treat immune-mediated diseases, reported on Monday that its experimental drug helped patients with a chronic skin condition in an initial and closely watched clinical trial. Among patients given a 120-mg dose, 10 of 12 had a complete response to treatment.
Hospital Pharmacy Europe
JULY 6, 2023
With Hospital Pharmacy Europe ’s inaugural Clinical Excellence in Respiratory Care event in conjunction with Hospital Healthcare Europe fast approaching, there are just a few days left to register. The post Time running out to register for MDT respiratory event appeared first on Hospital Pharmacy Europe.
pharmaphorum
JANUARY 15, 2021
Latest data give hope that the vaccine could be added to the campaign after phase 1/2a data showed that the shot provided an immune response that lasted for at least 71 days, the duration of time measured in the study involving patients aged 18-55 years. J&J expects to file with the FDA first, followed by other regulators.
Pharmacy Times
NOVEMBER 29, 2022
Treatment with immune checkpoint inhibitors have the potential for immune-related adverse events, such as psoriasis.
STAT
DECEMBER 12, 2023
Researchers also found that while adding Darzalex increased the rate of certain side effects, such as diarrhea and low immune cell counts, these adverse events were manageable and didn’t lead to more participants leaving the study. Continue to STAT+ to read the full story…
European Pharmaceutical Review
MARCH 26, 2024
Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition.
European Pharmaceutical Review
AUGUST 2, 2023
This is an additional ingredient designed to trigger a stronger immune response. The vaccine demonstrated a strong immune response in the trial. In a clinical trial, this vaccine was shown to faciliate a strong immune response against the Omicron BA.1 1 variant, in addition to the original 2020 strain.
Fierce Pharma
JUNE 29, 2023
By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday. While Dupixent often steals the show, Sanofi isn’t sleeping on its vaccine franchise. |
Pharma Times
APRIL 20, 2023
IMM-1-104 found to be well tolerated with no dose limiting toxicities or serious adverse events
Pharmacy Times
DECEMBER 9, 2024
Panelists discuss how bispecific antibody therapies in relapsed/refractory multiple myeloma commonly present with cytokine release syndrome (CRS), immune effector cellassociated neurotoxicity syndrome (ICANS), and increased infection risks, while talquetamab specifically exhibits distinctive adverse events including nail changes, skin reactions, and (..)
Pharmacy Times
DECEMBER 6, 2022
Biomarker testing and management of immune-related adverse events are key roles for pharmacists.
PharmaShots
APRIL 5, 2023
Shots: The P-IIb dose-finding study evaluates vidofludimus calcium vs PBO in patients at 78 study sites in the US and EU The 50wk. maintenance phase results showed a dose-linear increase in clinical remission, 10 & 30mg, qd of vidofludimus calcium showed clinical remission rate (42.3% & 61.5%
Pharmaceutical Technology
NOVEMBER 14, 2022
In lupus, the body’s immune system starts to attack its own cells. Saphnelo is also being studied in a Phase III trial in lupus nephritis, where a person’s immune system targets the kidneys, eventually leading to kidney failure. As per AstraZeneca's recent Q3 earnings, Saphnelo has yielded $69 million to date this year.
Hospital Pharmacy Europe
JULY 18, 2023
The primary outcome of interest was a physician-verified positive immune-mediated oral penicillin challenge within one hour after the intervention. In the five days following the oral penicillin challenge, a total of nine immune-mediated adverse events were recorded in the intervention group and 10 in the control group.
European Pharmaceutical Review
JUNE 27, 2023
Participants with greater than 90 days of follow-up had elimination of severe hypoglycaemic events in the evaluation period. It is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. This eliminates the need for immunosuppression.
European Pharmaceutical Review
JULY 13, 2023
The field of immunotherapy is constantly evolving with the ultimate goal to develop new treatments that help the body’s immune system fight cancer. Immune cells, such as T cells and natural killer (NK) cells, have the inherent ability to combat diseases, including cancer, but are often inhibited by the body’s own suppressive mechanisms.
pharmaphorum
NOVEMBER 27, 2024
The 10th Innate Killer Summit is a premier event organised by Hanson Wade, bringing together experts and thought leaders in the field of innate immunity and natural killer cells. Learn more about this event and how it can benefit you.
pharmaphorum
APRIL 12, 2021
Preclinical and early clinical data for modulators of the STING & TLR plus other innate immune checkpoint inhibitors has been hugely promising. View the event guide now for the full agenda details and speaker faculty. View the full event guide now. The post STING & TLR Targeting Therapies Summit appeared first on.
The Checkup by Singlecare
AUGUST 29, 2024
How Dupixent works in the body It’s still unclear what causes atopic dermatitis , the most common form of adult and pediatric eczema, but it’s commonly regarded as an immune system and skin barrier condition. Those intruders trigger the immune system, which releases certain proteins that cause skin inflammation.
pharmaphorum
SEPTEMBER 11, 2022
With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”
European Pharmaceutical Review
OCTOBER 25, 2024
The monoclonal antibody therapy was reported to be well tolerated, with most treatment emergent adverse events (TEAE) Grade 1 or 2, according to the findings. These promising data support continued evaluation of ZL-1310 as a monotherapy in the dose-expansion phase of the ongoing Phase I clinical trial and in combination.”
pharmaphorum
FEBRUARY 8, 2021
It works by using inactivated viral particles to expose the immune system, which mounts an immune response that fights off the active virus in the event of an infection. Brazilian clinical trial results published last month showed the vaccine, dubbed Coronavac, is just over 50% effective.
European Pharmaceutical Review
SEPTEMBER 22, 2022
The removal of HIV DNA from the cellular genome is essential to effecting a cure; the virus takes up long-term residence in tissue reservoirs, where it hides, evading the immune system and escaping antiretroviral therapy. As a result, HIV can persist in tissue reservoirs for years.
pharmaphorum
APRIL 16, 2021
The 2 nd Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better modulate, measure and predict immune response to your gene therapy candidate. View the full event guide now for full meeting details! Regulatory considerations for immune responses to gene therapies with the US FDA.
pharmaphorum
NOVEMBER 15, 2021
Arriving at a critical point for TIGIT development, the 2nd Annual TIGIT Therapies Summit is the definitive industry-led event focused on propelling this next-generation inhibitor to clinical use. Plus 2 add on workshops: • Elucidating the anti-tumor immunity of other immune checkpoint inhibitors in oncology.
pharmaphorum
NOVEMBER 29, 2022
Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. T cells are known to mediate anti-tumor immune responses. For that reason, they have become the key target of immune checkpoint therapies, like PD-(L)1 agents. No serious adverse events were observed.
pharmaphorum
MAY 3, 2022
Learn all there is to know about the immune cell engager landscape, including clinical achievements, potential response predictors, and novel immune cell-based engager therapeutic discoveries. Download the full event guide to find out more. The post 4th Annual Cell Engager Summit | May 24-26 | Boston, MA appeared first on.
pharmaphorum
AUGUST 31, 2022
In May, a Phase 2 study started, comparing Kaiku’s electronic patient-reported outcome (ePRO) approach to evaluating immune-related adverse events to the standard model of care in cancer patients treated with checkpoint inhibitor drugs, with results due towards the end of 2023 or in early 2024.
European Pharmaceutical Review
OCTOBER 7, 2022
UC is an Inflammatory Bowel Disease (IBD) that makes immune system attack the gastrointestinal (GI) tract. Zeposia ® reduces the capacity of lymphocytes to emerge from lymph nodes, reducing the number of lymphocytes (immune cells created in blood marrow) circulating in the blood. percent versus 6 percent. percent vs 18.5 percent vs 5.6
pharmaphorum
MAY 10, 2021
At the moment, there’s no indication that the cases are linked to the vaccine itself, but the EMA has asked the companies to provide “further detailed data, including an analysis of the events according to age and gender,” as it looks into the signal.
Digital Pharmacist
DECEMBER 20, 2023
Host Virtual Events From live videos and wellness classes to educational webinars and industry conferences, hosting a virtual event is a low-cost way to expand your online audience. Another way to advertise your pharmacy to your local audience is by sponsoring local events, from health fairs to community outings.
The Checkup by Singlecare
OCTOBER 4, 2024
However, it may weaken the body’s immune response and possibly worsen the side effects of fluconazole. It also treats systemic infections like cryptococcal meningitis in people with weakened immune systems. Chronic alcohol consumption may weaken the immune response , making it more difficult for the body to fight off illnesses.
Pharmacy Is Right For Me
SEPTEMBER 24, 2024
In my first year of pharmacy school, I joined UNC’s local SNPhA chapter as the Power to End Stroke Co-Chair and planned events ranging from blood pressure and blood glucose screenings to a step-challenge to get our community moving!
pharmaphorum
NOVEMBER 11, 2022
Download the full event guide here for the official agenda. Marc Pelletier , Senior Principal Scientist – Translational Immune Oncology, Novartis. Kate Fitzgerald , Professor & Vice Chair, Department of Medicine, Division of Innate Immunity, University of Massachusetts Chan Medical School.
pharmaphorum
MARCH 18, 2021
And because the vaccine is effective in preventing COVID-19 disease – which in itself is a cause of blood clots – it “likely reduces the risk of thrombotic events overall.”. PRAC meanwhile says is also looking into reports of cases of immune thrombocytopenia (ITP) with vaccines available in the US.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content